June 26, 2013
Pluristem (PSTI) Cha Bio Strategic Partnership and Licensing Agreement
June 18, 2013
Opexa (OPXA) files $17.5 M offering
June 14, 2013
Companies and a university are moving to offer cheaper and broader genetic testing for breast cancer risk
June 12, 2013
ThermoGenesis’s (KOOL) AXP® AutoXpress® System (AXP) was selected by the United Kingdom's NHS Blood and Transplant
June 6, 2013
Verastem (VSTM) appoints Chief Executive Officer
April 30, 2013
Fibrocell (OTC: FCSCD) 1 for 25 stock reverse
April 13, 2013
BioLife Solutions (OTC: BLFS), a life sciences tools company
April 11, 2013
NeoStem (NYSE MKT: NBS) telling the story of hope and healing at the Vatican
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.